{"transactions":[{"id":4624345,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Warrant (Right to Buy)","published_at":"2026-09-18T21:04:53.000Z","date":"2026-06-30","kind":"other","planned":false,"acquired":true,"shares":85910,"price":0.582,"value":49999.62,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"On June 30, 2026, the Reporting Person participated in the PIPE Offering indirectly through V-Co Investors 4 LLC (\"V-Co 4\"), in which he acquired a membership interest. His indirect interest in V-Co 4 represents approximately $50,000 of the aggregate purchase price paid by V-Co 4, corresponding to 85,910 shares of Series A Convertible Preferred Stock and Warrants to purchase 85,910 shares of Common Stock purchased of record by V-Co 4. The securities reported are held of record by V-Co 4. The Preferred Stock is convertible at any time at the holder's election, subject to a beneficial ownership limitation, and has no expiration date. The warrants are exercisable at $0.456 per share through June 30, 2031. The $0.582 price reported is the per-unit price in the PIPE Offering. The Reporting Person disclaims beneficial ownership of the securities held by V-Co 4 except to the extent of his pecuniary interest therein."}],"balance_after":85910,"derivative":{"exercise_price":0.456,"exercise_date":"2026-06-30","expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":85910},"source":{"system":"sec-edgar","filing":"0001493152-26-043383","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226043383/ownership.xml","form_type":"4"}},{"id":4624344,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Preferred Stock","published_at":"2026-09-18T21:04:53.000Z","date":"2026-06-30","kind":"other","planned":false,"acquired":true,"shares":85910,"price":0.582,"value":49999.62,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"On June 30, 2026, the Reporting Person participated in the PIPE Offering indirectly through V-Co Investors 4 LLC (\"V-Co 4\"), in which he acquired a membership interest. His indirect interest in V-Co 4 represents approximately $50,000 of the aggregate purchase price paid by V-Co 4, corresponding to 85,910 shares of Series A Convertible Preferred Stock and Warrants to purchase 85,910 shares of Common Stock purchased of record by V-Co 4. The securities reported are held of record by V-Co 4. The Preferred Stock is convertible at any time at the holder's election, subject to a beneficial ownership limitation, and has no expiration date. The warrants are exercisable at $0.456 per share through June 30, 2031. The $0.582 price reported is the per-unit price in the PIPE Offering. The Reporting Person disclaims beneficial ownership of the securities held by V-Co 4 except to the extent of his pecuniary interest therein."}],"balance_after":85910,"source":{"system":"sec-edgar","filing":"0001493152-26-043383","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226043383/ownership.xml","form_type":"4"}},{"id":1348816,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-27T21:47:13.000Z","date":"2024-11-26","kind":"grant","planned":false,"acquired":true,"shares":315421,"price":2.64,"value":832711.44,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On September 7, 2024 (the \"Grant Date\"), the Reporting Person received a grant of 315,421 stock options, which grant was made under but subject to stockholder approval of the Issuer's 2024 Omnibus Equity Incentive Plan and such grant at the Issuer's 2024 Annual Meeting. Such meeting was held, and such stockholder approval was obtained, on November 26, 2024. One-third shall vest and become exercisable in three installments on each of the first, second and third anniversaries of the date of grant through September 7, 2027."}],"balance_after":364755,"derivative":{"exercise_price":2.64,"expiration_date":"2034-09-07","underlying":"Common Stock","underlying_shares":315421},"source":{"system":"sec-edgar","filing":"0001493152-24-048026","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315224048026/ownership.xml","form_type":"4"}},{"id":1466957,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-29T00:53:51.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":2.38,"value":47600.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On June 20, 2024 (the \"Grant Date\"), the Reporting Person received a grant of 20,000 stock options from the Issuer. One-fifth vested immediately and one-fifth will vest annually on each anniversary of the Grant Date through June 20, 2028."}],"balance_after":49334,"derivative":{"exercise_price":2.38,"expiration_date":"2029-06-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001493152-24-025688","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315224025688/ownership.xml","form_type":"4"}},{"id":1848621,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-06-21T01:58:39.000Z","date":"2023-06-20","kind":"purchase","planned":false,"acquired":true,"shares":14000,"price":0.53,"value":7420.0,"ownership":{"direct":true},"balance_after":86521,"source":{"system":"sec-edgar","filing":"0001493152-23-021910","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223021910/ownership.xml","form_type":"4"}},{"id":1848618,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-06-20T10:10:09.000Z","date":"2023-06-16","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":0.53,"value":2650.0,"ownership":{"direct":true},"balance_after":72521,"source":{"system":"sec-edgar","filing":"0001493152-23-021751","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223021751/ownership.xml","form_type":"4"}},{"id":1848617,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-06-20T10:10:09.000Z","date":"2023-06-16","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":0.54,"value":5400.0,"ownership":{"direct":true},"balance_after":67521,"source":{"system":"sec-edgar","filing":"0001493152-23-021751","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223021751/ownership.xml","form_type":"4"}},{"id":1848616,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-06-20T10:10:09.000Z","date":"2023-06-15","kind":"purchase","planned":false,"acquired":true,"shares":21,"price":0.5,"value":10.5,"ownership":{"direct":true},"balance_after":57521,"source":{"system":"sec-edgar","filing":"0001493152-23-021751","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223021751/ownership.xml","form_type":"4"}},{"id":1853765,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-06-15T23:15:31.000Z","date":"2023-06-14","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":0.49,"value":4900.0,"ownership":{"direct":true},"balance_after":57500,"source":{"system":"sec-edgar","filing":"0001493152-23-021525","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223021525/ownership.xml","form_type":"4"}},{"id":2075364,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-29T02:45:36.000Z","date":"2022-12-23","kind":"grant","acquired":true,"shares":150000,"price":0.48,"value":72000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"150,000 stock options granted on December 23, 2022. One-fifth vested immediately and one-fifth vests annually on each anniversary date through December 23, 2026."}],"balance_after":483334,"derivative":{"exercise_price":0.48,"expiration_date":"2027-12-23","underlying":"Common Stock","underlying_shares":483334},"source":{"system":"sec-edgar","filing":"0001493152-22-036727","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315222036727/ownership.xml","form_type":"4"}},{"id":2075363,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-29T02:45:36.000Z","date":"2022-12-23","kind":"grant","acquired":true,"shares":333334,"price":0.48,"value":160000.32,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"333,334 fully vested stock options granted on December 23, 2022."}],"balance_after":333334,"derivative":{"exercise_price":0.48,"expiration_date":"2027-12-23","underlying":"Common Stock","underlying_shares":333334},"source":{"system":"sec-edgar","filing":"0001493152-22-036727","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315222036727/ownership.xml","form_type":"4"}},{"id":2075362,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-29T02:45:36.000Z","date":"2022-12-23","kind":"purchase","acquired":true,"shares":20000,"price":0.5,"value":10000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares held by Coronado V Partners, LLC, of which the reporting person is a member and manager."}],"balance_after":47500,"source":{"system":"sec-edgar","filing":"0001493152-22-036727","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315222036727/ownership.xml","form_type":"4"}},{"id":2243616,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-06-03T10:08:33.000Z","date":"2022-06-01","kind":"purchase","acquired":true,"shares":4000,"price":1.83,"value":7320.0,"ownership":{"direct":true},"balance_after":27500,"source":{"system":"sec-edgar","filing":"0001493152-22-015773","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315222015773/ownership.xml","form_type":"4"}},{"id":2243615,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-06-03T10:08:33.000Z","date":"2022-05-31","kind":"purchase","acquired":true,"shares":8000,"price":2.03,"value":16240.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in four separate transactions ranging from $2.02 to $2.035 on May 31, 2022. The reporting person undertakes to provide to Vivos Therapeutics, Inc., any security holder of Vivos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4."}],"balance_after":23500,"source":{"system":"sec-edgar","filing":"0001493152-22-015773","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315222015773/ownership.xml","form_type":"4"}},{"id":2368249,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-28T23:54:57.000Z","date":"2022-02-25","kind":"grant","acquired":true,"shares":125000,"price":3.27,"value":408750.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"125,000 stock options granted on February 25, 2022. One-fifth vested immediately and one-fifth vests annually on each anniversary date through February 25, 2026."}],"balance_after":125000,"derivative":{"exercise_price":3.27,"expiration_date":"2027-02-25","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001493152-22-005662","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315222005662/ownership.xml","form_type":"4"}},{"id":2397034,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-15T02:21:10.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":125000,"price":5.64,"value":705000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"An option for the purchase of 125,000 shares was granted on June 16, 2021. The option vests one fifth immediately and one-fifth annually on each anniversary date through June 16, 2025."}],"balance_after":125000,"derivative":{"exercise_price":5.64,"expiration_date":"2026-06-26","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001493152-22-004603","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315222004603/ownership.xml","form_type":"5"}},{"id":2561447,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-09-22T19:09:28.000Z","date":"2021-09-21","kind":"purchase","acquired":true,"shares":5000,"price":4.31,"value":21550.0,"ownership":{"direct":true},"balance_after":15500,"source":{"system":"sec-edgar","filing":"0001493152-21-023354","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315221023354/ownership.xml","form_type":"4"}},{"id":2597071,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-08-18T19:47:51.000Z","date":"2021-08-17","kind":"purchase","acquired":true,"shares":5000,"price":3,"value":15000.0,"ownership":{"direct":true},"balance_after":10500,"source":{"system":"sec-edgar","filing":"0001493152-21-020536","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315221020536/ownership.xml","form_type":"4"}},{"id":2696485,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-05-26T01:45:20.000Z","date":"2021-05-25","kind":"purchase","acquired":true,"shares":4000,"price":5.38,"value":21520.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.335 to $5.40."}],"balance_after":5500,"source":{"system":"sec-edgar","filing":"0001493152-21-012901","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315221012901/ownership.xml","form_type":"4"}},{"id":2932442,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-12-23T23:53:04.000Z","date":"2020-12-23","kind":"purchase","acquired":true,"shares":1000,"price":7.2669,"value":7266.9,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"1,000 shares purchased in prices ranging from $7.25 through $7.2798 per share."}],"balance_after":1500,"source":{"system":"sec-edgar","filing":"0001493152-20-024277","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315220024277/ownership.xml","form_type":"4"}},{"id":2945853,"issuer":{"id":8396,"kind":"organization","name":"Vivos Therapeutics, Inc."},"owners":[{"id":85592,"kind":"person","name":"Huntsman Ronald Kirk","position":1,"cik":"0001835498","reported_name":"Huntsman Ronald Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-12-14T13:45:32.000Z","date":"2020-12-11","kind":"purchase","acquired":true,"shares":500,"price":8.5,"value":4250.0,"ownership":{"direct":true},"balance_after":500,"source":{"system":"sec-edgar","filing":"0001493152-20-023466","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315220023466/ownership.xml","form_type":"4"}}]}